Comparative Pharmacology
Head-to-head clinical analysis: LAROTID versus STAPHCILLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAROTID versus STAPHCILLIN.
LAROTID vs STAPHCILLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Larotrectinib is a selective inhibitor of tropomyosin receptor kinase (TRK) A, B, and C. It inhibits TRK kinase activity by binding to the ATP-binding site, leading to inhibition of downstream signaling pathways, which results in reduced cell proliferation and tumor growth in tumors with NTRK gene fusions.
Semisynthetic penicillin; inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
Larotrectinib 100 mg orally twice daily, with or without food, for adult patients.
1-2 g IV every 4-6 hours.
None Documented
None Documented
30 minutes; prolonged in renal impairment (up to 20 hours in anuria).
0.5-1 hour in adults with normal renal function; prolonged to 2-4 hours in renal impairment. Infants: 1-2 hours.
Renal: 70-80% unchanged by glomerular filtration and tubular secretion; Biliary/Fecal: <10% as inactive metabolites.
Primarily renal (70-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary excretion (<5%) and fecal elimination (<1%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic